Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Asthma, Bronchospasm

In brief

This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover and dose-ranging design. This study aims to evaluate the efficacy and initial safety profiles, and to identify the optimum dose of A006, from a select dose-range for future clinical PK/PD and Phase III studies. This study is to be conducted in generally healthy, adult subjects who have mild-to-moderate persistent asthma for at least 6 months prior to Screening.

Key facts

Study ID
NCT01174732
Run by
Amphastar Pharmaceuticals, Inc.
People needed
26
Starts
2010-07-01
Expected to finish
2011-01-01
Last updated by the study team
2017-04-19

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.